LY-334370

LY-334370
Names
	Preferred IUPAC name 4-Fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide
	Other names LY-334,370
Identifiers
CAS Number	182563-08-2 ;
3D model (JSmol)	Interactive image;
ChemSpider	4470773 ;
IUPHAR/BPS	20; 151;
MeSH	C108218
PubChem CID	5311258;
UNII	5Q7I1WL2UY ;
CompTox Dashboard (EPA)	DTXSID40415518 ;
	InChI InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26) Key: MDMJLMDBRQXOOI-UHFFFAOYSA-N ; InChI=1/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26) Key: MDMJLMDBRQXOOI-UHFFFAOYAA;
	SMILES CN1CCC(c2c3cc(N([H])C(c4ccc(F)cc4)=O)ccc3n([H])c2)CC1;
Properties
Chemical formula	C21H22FN3O
Molar mass	351.425 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

LY-334370 is a selective 5-HT_1F receptor agonist^[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.^[2] The drug showed efficacy in a phase II clinical trial^[3] but further development was halted due to toxicity detected in animals.^[4]

^ Dupuis DS, Colpaert FC, Pauwels PJ (1998). "G-protein activation at 5-HT_1A receptors by the 5-HT_1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines". Br. J. Pharmacol. 124 (2): 283–90. doi:10.1038/sj.bjp.0701832. PMC 1565387. PMID 9641544.
^ Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). "Possible antimigraine mechanisms of action of the 5HT_1F receptor agonist LY-334,370". Cephalalgia. 19 (10): 851–8. doi:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103. S2CID 8439008.
^ Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). "Selective seratonin 1F (5-HT_1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial". Lancet. 358 (9289): 1230–4. doi:10.1016/S0140-6736(01)06347-4. PMID 11675061. S2CID 39926402.
^ Ramadan NM, Buchanan TM (2006). "New and future migraine therapy". Pharmacol. Ther. 112 (1): 199–212. doi:10.1016/j.pharmthera.2005.04.010. PMID 16797716.

[pmid9641544-1] Dupuis DS, Colpaert FC, Pauwels PJ (1998). "G-protein activation at 5-HT_1A receptors by the 5-HT_1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines". Br. J. Pharmacol. 124 (2): 283–90. doi:10.1038/sj.bjp.0701832. PMC 1565387. PMID 9641544.

[pmid10668103-2] Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). "Possible antimigraine mechanisms of action of the 5HT_1F receptor agonist LY-334,370". Cephalalgia. 19 (10): 851–8. doi:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103. S2CID 8439008.

[pmid11675061-3] Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). "Selective seratonin 1F (5-HT_1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial". Lancet. 358 (9289): 1230–4. doi:10.1016/S0140-6736(01)06347-4. PMID 11675061. S2CID 39926402.

[pmid16797716-4] Ramadan NM, Buchanan TM (2006). "New and future migraine therapy". Pharmacol. Ther. 112 (1): 199–212. doi:10.1016/j.pharmthera.2005.04.010. PMID 16797716.

[1]

[2]

[3]

[4]